Prostamax (Prostamax (Prostate Peptide Bioregulator))
A short peptide bioregulator from the Khavinson family targeted at prostate tissue. Used in the bioregulator community to support prostate function and male urogenital health in short repeated courses.
How it works
As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue.
Key facts
- Molecular weight: ~ (short peptide)
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Often used by men for prostate/urogenital support.
Reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Prostate peptide bioregulators (2015): Reported to support prostatic tissue function and urogenital health in regional research studies.
Compare Prostamax
Research and educational reference only. Not medical advice.